Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04274738
Title A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors X4 Pharmaceuticals
Indications

Waldenstroem's macroglobulinemia

Therapies

Ibrutinib + X4P-001

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.